PCiB-2 is a small molecule inhibitor capable of inhibiting phosphatidylcholine (PC) biogenesis with IC50 of 2.0 uM, inhibits the phosphatidylethanolamine (PE) methyltransferase activity of Cho2, induces mitochondrial division.

PCiB-3 is a small molecule inhibitor capable of inhibiting phosphatidylcholine (PC) biogenesis with IC50 of 0.4 uM, inhibits the phosphatidylethanolamine (PE) methyltransferase activity of Cho2.

PDDC is the first potent, selective, orally-available, and brain-penetrable nSMase2 (neutral sphingomyelinase 2) inhibitor with pIC50 of 6.57.

PEPCKi is a small molecule inhibitor of hosphoenolpyruvate carboxykinase (PEPCK), blocks lactate utilization and impairs tumor growth in colorectal cancer.

PF-07208254 (PF 07208254) is a potent, allosteric branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor with in vitro IC50 of 110 nM and Ki of 54 nM.

PF-07247685 (PF-07247685) is a potent, allosteric branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor with in vitro IC50 of 0.86 nM, and SPR Kd of 0.68 nM.

PFKL activator NA-11 is a small-molecule, selective PFKL activator, inhibits the NOX2-dependent oxidative burst in neutrophils by activating the glycolytic enzyme phosphofructokinase-1 liver type (PFKL).

Pixatimod (PG545) is a heparan sulfate (HS) mimetic and anticancer agent and a potent inhibitor of heparanase.

PPA-904 is a specific phenothiazine photosensitizer in photodynamic therapy (PDT) research, especially topical application for cutaneous leishmaniasis in vivo.

Varoglutamstat (PQ912) is a potent glutaminyl cyclase (QC) inhibitor with Ki values of 20-65 nM for human, rat, and mouse QC activity.

PRG-A01 is a chemical inhibitor against SOD1 misfolding and aggregation, inhibits the neuronal cell death caused by mutant-SOD1 overexpression.

PSB-22034 is a potent, selective agonist of MAS-related Gq protein-coupled receptor X4 (MRGPRX4) with EC50 of 11.2 nM/32.0 nM in Ca2+ assay/β-arrestin assays (variant 83S), respectively.

PSB-22040 is a potent, selective agonist of MAS-related Gq protein-coupled receptor X4 (MRGPRX4) with EC50 of 19.2 nM/30.0 nM in Ca2+ assay/β-arrestin assays (variant 83S), respectively.

PSB-CB-148 is a potent, selective antagonist of GPR18.

PSB-CB-27 is a potent, selective antagonist of GPR18 with IC50 of 650 nM, shows no inhibition on GPR55 and low affinity for CB1/CB2 receptors.

PSB-KK-1415 is a selective GPR18 agonist with EC50 of 19.1 nM (hGPR18) in β-arrestin recruitment assays, shows no activity against GPR55.

PT91 is a small-molecule GPR27 (SREB1) agonist with pEC50 of 6.15 (human GPR27) in β-arrestin 2 recruitment-based firefly luciferase complementation assay, Emax=100%.

PTI-125 (Simufilam, Sumifilam) is a small molecule targeting scaffolding protein filamin A (FLNA), preferentially binds altered FLNA and restores its native conformation.

PXS-4748 (PXS4748) is a potent, selective and irreversible pan-lysyl oxidase (pan-LOX) inhibitor with IC50 of 2.0 uM and 3.2/0.6/1.4/0.2 uM for bovine (aorta) LOX and rh LOXL1/2/3/4, respectively.

PXS-5129A is the pro-drug form of PXS-5120A, a potent, selective, irreversible inhibitor of Lysyl oxidase-like 2 (LOXL2).

PXS-5505 dihydrochloride monohydrate is an orally available, small-molecule, irreversible inhibitor of all lysyl oxidases (pan-LOX) family members, with potential antifibrotic activity.

PXS-6302 (PXS6302) is a potent, irreversible pan-lysyl oxidase (pan-LOX) inhibitor with IC50 of 3.7 uM and 3.4/0.4/1.5/0.3 uM for bovine (aorta) LOX and rh LOXL1/2/3/4, respectively.